United Therapeutics Corporation (NASDAQ:UTHR) Shares Purchased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. raised its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 27.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,059 shares of the biotechnology company's stock after buying an additional 875 shares during the period. PNC Financial Services Group Inc.'s holdings in United Therapeutics were worth $1,251,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Jupiter Asset Management Ltd. acquired a new stake in shares of United Therapeutics during the first quarter worth approximately $15,607,000. Blueshift Asset Management LLC acquired a new stake in shares of United Therapeutics during the first quarter worth approximately $523,000. US Bancorp DE increased its holdings in shares of United Therapeutics by 12.2% during the first quarter. US Bancorp DE now owns 1,971 shares of the biotechnology company's stock worth $608,000 after buying an additional 215 shares in the last quarter. Natixis Advisors LLC increased its holdings in shares of United Therapeutics by 763.4% during the first quarter. Natixis Advisors LLC now owns 118,582 shares of the biotechnology company's stock worth $36,556,000 after buying an additional 104,847 shares in the last quarter. Finally, Seizert Capital Partners LLC grew its stake in shares of United Therapeutics by 203.3% during the first quarter. Seizert Capital Partners LLC now owns 121,970 shares of the biotechnology company's stock valued at $37,600,000 after purchasing an additional 81,752 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the transaction, the director owned 19,384 shares in the company, valued at $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock worth $24,618,359 over the last 90 days. Company insiders own 10.30% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on UTHR. HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. Bank of America reduced their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target on the stock. Finally, Wells Fargo & Company lowered their price objective on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $382.00.

United Therapeutics Stock Up 2.8%

Shares of NASDAQ UTHR traded up $8.33 during trading on Wednesday, reaching $309.72. 579,471 shares of the company traded hands, compared to its average volume of 520,965. The firm has a 50 day simple moving average of $295.69 and a 200-day simple moving average of $310.03. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market capitalization of $13.97 billion, a PE ratio of 12.09, a P/E/G ratio of 4.55 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the previous year, the business posted $5.85 EPS. United Therapeutics's revenue was up 11.7% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.